Eli Lilly’s LLY recent announcement to acquire Verve Therapeutics, Inc VERV, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, has put the spotlight on ...
Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...
Zacks Investment Research on MSN
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?
Beam Therapeutics BEAM and Intellia Therapeutics NTLA are clinical-stage companies developing investigational gene therapies. While BEAM’s pipeline candidates are still in early-stage development, ...
On Tuesday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Verve Therapeutics, Inc. (NASDAQ:VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. Lilly ...
Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research and Evaluation (CBER) faced another abrupt leadership transition following ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, Canaccord Genuity analyst John Newman reaffirmed a Buy rating on ...
Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...
Editas Medicine (NASDAQ:EDIT) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, 2025, Clear Street raised its price target on Editas Medicine (NASDAQ:EDIT) to ...
Ark Invest bought shares of Alibaba, Intellia Therapeutics, and Baidu on Monday. Alibaba and Baidu are surging Chinese e-commerce stocks that have emerged as AI plays. Intellia shares have almost ...
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...
No-moat Intellia Therapeutics reported first-quarter results in line with our expectations, as its gene editing pipeline is continuing to make progress. The company is on track to complete enrollment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback